Wearable Continuous Glucose Monitor (CGM) market outlook remains highly attractive, driven by expanding diabetic populations, reimbursement advances, and consumer demand for seamless health tracking. Competitive intensity is escalating as legacy players such as Abbott and Dexcom launch next‑generation sensors, while emerging startups leverage AI‑driven analytics to differentiate. Over the next five to ten years, we anticipate steady CAGR above 12%, underpinned by integration with digital therapeutics and insurance coverage broadening across geographies. Innovation is concentrated on miniaturization, multi‑analyte platforms, and closed‑loop insulin delivery, creating a pipeline that will sustain premium pricing. Demand currently outpaces supply in high‑growth regions (North America, Europe, Asia‑Pacific), but manufacturing bottlenecks in semiconductor components could tighten the balance. Key risk factors include regulatory delays, data‑privacy concerns, and potential market saturation if reimbursement policies tighten. Decision‑makers should prioritize partnerships that accelerate sensor miniaturization and monitor the evolving policy landscape to mitigate these risks. Overall, the sector promises robust revenue expansion, provided firms navigate the regulatory and supply-chain challenges effectively.
